Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

被引：0
|
作者：
Joan Maurel
Santiago Sánchez-Cabús
Berta Laquente
Lydia Gaba
Laura Visa
Joan Fabregat
Ignacio Povés
Susana Roselló
Roberto Díaz-Beveridge
Marta Martín-Richard
Javier Rodriguez
Luis Sabater
Carles Conill
María Cambray
Ana Reig
Juan Ramón Ayuso
Carlos Valls
Antonio Ferrández
Josep Antoni Bombí
Angels Ginés
Xabier García-Albéniz
Laureano Fernández-Cruz
机构：
[1] IDIBAPS,Surgical Department, Hospital Clínic Barcelona
[2] University of Barcelona,Medical Oncology Department
[3] Institut Català d’Oncologia,Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group
[4] IDIBAPS,Department of Oncology
[5] University of Barcelona,Surgical Department
[6] Hospital Mar,Surgical Department
[7] Hospital Bellvitge,Medical Oncology Department
[8] Hospital del Mar,Medical Oncology Department
[9] Hospital Clínico Valencia,Medical Oncology Department
[10] Hospital La Fe,Medical Oncology Department
[11] Hospital Sant Pau,Surgical Department
[12] Hospital Clínico Universitario Navarra,Radiotherapy Oncology Department, Hospital Clínic Barcelona
[13] Hospital Clínico Valencia,Radiotherapy Oncology Department
[14] IDIBAPS,Radiotherapy Oncology Department
[15] University of Barcelona,Radiology Department, Hospital Clínic Barcelona
[16] Institut Català d’Oncologia,Radiology Department
[17] Hospital Mar,Pathology Department
[18] IDIBAPS,Pathology Department, Hospital Clínic Barcelona
[19] University of Barcelona,Gastrointestinal Department, Hospital Clínic Barcelona
[20] Hospital Bellvitge,undefined
[21] Hospital Clínico Valencia,undefined
[22] IDIBAPS,undefined
[23] University of Barcelona,undefined
[24] IDIBAPS,undefined
[25] University of Barcelona,undefined
[26] Harvard T.H. Chan School of Public Health,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 82卷
关键词：
Neoadjuant; Pancreatic; Adenocarcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：935 / 943
页数：8
相关论文
共 50 条
  • [1] Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)
    Maurel, Joan
    Sanchez-Cabus, Santiago
    Laquente, Berta
    Gaba, Lydia
    Visa, Laura
    Fabregat, Joan
    Poves, Ignacio
    Rosello, Susana
    Diaz-Beveridge, Roberto
    Martin-Richard, Marta
    Rodriguez, Javier
    Sabater, Luis
    Conill, Carles
    Cambray, Maria
    Reig, Ana
    Ramon Ayuso, Juan
    Valls, Carlos
    Ferrandez, Antonio
    Antoni Bombi, Josep
    Gines, Angels
    Garcia-Albeniz, Xabier
    Fernandez-Cruz, Laureano
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (06) : 935 - 943
  • [2] Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10-03 trial
    Laquente, B.
    Conill, C.
    Fabregat, J.
    Cambray, M.
    Ayuso, J. R.
    Valls, C.
    Bombi, J. A.
    Serrano, T.
    Ferrandez, A.
    Poves, I.
    Sabater, L.
    Montagut, C.
    Rosello, S.
    Martin-Richard, M.
    Diaz-Beveridge, R.
    Rodriguez, J.
    Gallego, R.
    Garcia-Albeniz, X.
    Fernandez-Cruz, L.
    Maurel, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S416 - S416
  • [3] Neoadjuvant gemcitabine, erlotinib, and hypofractionated radiation therapy for potentially resectable pancreatic cancer: A pilot study
    Cardenes, H. R.
    Chiorean, E. G.
    Perkins, S.
    DeWitt, J.
    Schmidt, C. M.
    Crowell, P.
    Yip-Schneider, M.
    Zyromski, N.
    Cramer, H.
    Howard, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] The biomarkers of gemcitabine and erlotinib treatment in advanced pancreatic cancer
    Irie, Kuniyasu
    Ueno, Makoto
    Kobayashi, Satoshi
    Gouda, Yoshihiro
    Ohkawa, Shinichi
    Manabu, Morimoto
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] RANDOMIZED CROSS-OVER AIO PHASE III TRIAL COMPARING GEMCITABINE PLUS ERLOTINIB FOLLOWED BY CAPECITABINE VS. CAPECITABINE PLUS ERLOTINIB FOLLOWED BY GEMCITABINE IN ADVANCED PANCREATIC CANCER
    Boeck, S.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Kettner, E.
    Maerten, A.
    Winkelmann, C.
    Klein, S.
    Kojouharoff, G.
    Jung, A.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 233 - 233
  • [6] Efficacy and toxicity of gemcitabine-erlotinib in the metastatic pancreatic cancer treatment
    Mejia, L.
    Vicente, I.
    Lopez, M.
    Antonino, G.
    Garcia del Busto, N.
    Sanchez, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 989 - 989
  • [7] A PILOT TRIAL OF GEMCITABINE IN COMBINATION WITH CAPECITABINE OR ERLOTINIB COMPARED TO GEMCITABINE ALONE IN PATIENTS WITH ADVANCED PANCREATIC CANCER
    Cho, J. Y.
    Lim, J. Y.
    Lee, S. J.
    Lee, D. K.
    Park, J. S.
    Yoon, D. S.
    Min, Y. H.
    ANNALS OF ONCOLOGY, 2012, 23 : 240 - 240
  • [8] Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer
    Mie, Takafumi
    Sasaki, Takashi
    Takeda, Tsuyoshi
    Okamoto, Takeshi
    Mori, Chinatsu
    Furukawa, Takaaki
    Yamada, Yuto
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Sasahira, Naoki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (09) : 1416 - 1422
  • [9] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Lee, Suee
    Kwon, Hyuk Chan
    Lee, Gyeong Won
    Go, Seil
    Kang, Myoung Hee
    Cha, Young Joo
    Kang, Jung Hun
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2371 - 2376
  • [10] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    In Gyu Hwang
    Joung-Soon Jang
    Sung Yong Oh
    Suee Lee
    Hyuk Chan Kwon
    Gyeong Won Lee
    Seil Go
    Myoung Hee Kang
    Young Joo Cha
    Jung Hun Kang
    Investigational New Drugs, 2012, 30 : 2371 - 2376
12345